Viz.ai

Viz.ai is a healthcare startup that uses artificial intelligence to identify early signs of stroke.
Corporate history and product
The company was co-founded by David Golan and Dr. Chris Mansi in 2016, after David suffered a brain malady.
Viz.ai, based in San Francisco and Israel, developed the first software for synchronizing healthcare and utilize AI to reduce treatment and intervention time for those suffering from large vessel occlusions (LVOs). Viz.ai allows doctors and medical professionals to upload CT angiogram images and determine whether there has been a stroke within minutes of photo processing. Once confirmed, an alert is sent to the treating physician and surgical teams. During a stroke, 2 million brain cells die every minute, and strokes are the number one cause of disability in the United States, making timing of intervention critical.
The Viz technology is used in 300 medical facilities across the United States, including those specializing in the treatment of strokes, including The Southeast Regional Stroke Center at Erlanger in University of Tennessee’s Erlanger Medical Center in Chattanooga.
Approvals, Developments, and Partnerships
Viz.ai gained FDA approval, 510(k) in 2018, as the first computer-based triage and notification software. The company’s CT app generating color maps of the brain's blood supply and calculating time plots, has also been approved and made compatible with Viz.ai.
The company partnered with Medtronic, the largest medical device company in the world, to accelerate the adoption of Viz.ai’s technology in additional hospitals and reduce treatment time for stroke victims.
Funding and Awards
In July 2018, Viz.ai received $21 million in series A funding.
In 2019, the company earned $50 million in series B funding, led by Greenoaks Capital Partners, as well as Alphabet, Charles River Ventures (CRV), Threshold Ventures, GV (formerly Google Ventures), and Kleiner Perkins. The 2019 funding is being used to expand the technology to additional hospitals and the treatment of other diseases.
Also in 2019, Viz.ai was named one of Forbe’s AI 50: America’s Most Promising AI Companies.

Main Menu

See Also

Main Menu